Does Taking Emergency Contraception Affect Breastfeeding?

Emergency contraception—commonly known as the “morning-after pill”—is occasionally needed by breastfeeding individuals following unprotected intercourse or contraceptive failure. A key clinical concern is whether these medications affect lactation or pose risks to the nursing infant.

The two primary types of emergency contraceptive pills used globally are levonorgestrel (a progestin-only agent) and ulipristal acetate (a selective progesterone receptor modulator). Both have been evaluated for safety during lactation. Current evidence, including data from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the American College of Obstetricians and Gynecologists (ACOG), indicates that neither levonorgestrel nor ulipristal acetate significantly alters milk production or composition. These agents are minimally excreted into breast milk, and the amounts ingested by the infant are considered pharmacologically negligible.

For levonorgestrel, studies show less than 0.1% of the maternal dose appears in breast milk over 24 hours. Ulipristal acetate demonstrates similarly low transfer; its short half-life and limited oral bioavailability in infants further reduce theoretical risk. Neither drug has been associated with adverse effects in breastfed infants in clinical surveillance or case series.

While no routine interruption of breastfeeding is recommended after taking either agent, some clinicians advise a brief, optional delay—such as waiting 24 hours after ulipristal acetate—as a precautionary measure, particularly in neonates or preterm infants. This is not evidence-based but reflects conservative clinical judgment in high-risk scenarios. For levonorgestrel, no such delay is necessary.

It is important to emphasize that emergency contraception does not replace ongoing contraceptive planning. Lactational amenorrhea offers only partial protection against pregnancy, and ovulation may resume before menses returns. Providers should counsel breastfeeding patients on safe, effective, and compatible long-term contraceptive options—including progestin-only methods, intrauterine devices (IUDs), and barrier techniques—during the postpartum period.